Comparative Pharmacology
Head-to-head clinical analysis: SEPTOCAINE versus XYLOCAINE 5 W GLUCOSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEPTOCAINE versus XYLOCAINE 5 W GLUCOSE 7 5.
SEPTOCAINE vs XYLOCAINE 5% W/ GLUCOSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Articaine is a local anesthetic of the amide type that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse conduction.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
SEPTOCAINE (articaine HCl 4% with epinephrine 1:100,000 or 1:200,000) dental infiltration or nerve block: 0.5–1.7 mL (20–68 mg articaine) per injection site; maximum adult dose: 7 mg/kg (up to 500 mg total).
Adult: 5-25 mL (250-1250 mg lidocaine) of 5% lidocaine with glucose 7.5% solution, administered by caudal or lumbar epidural injection, single dose. Max total dose: 1250 mg.
None Documented
None Documented
Terminal elimination half-life in adults is 2-4 hours. In neonates, it may be prolonged to 8-12 hours due to immature hepatic function.
1.5-2 hours (terminal); prolonged in heart failure, hepatic disease, or elderly; neonates 3-6 hours due to immature hepatic function.
Primarily hepatic metabolism; less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Hepatic metabolism (90% N-dealkylation by CYP1A2/CYP3A4 to monoethylglycinexylidide and glycinexylidide); renal excretion of metabolites and parent drug (<10% unchanged); <1% biliary/fecal.
Category C
Category C
Local Anesthetic
Local Anesthetic